BioSpace News Archive

Geneoscopy Inc., a life sciences company that develops diagnostic tests for gastrointestinal health, today announced positive results of their diagnostic in detecting both colorectal cancer and precancerous adenomas in a large, multicenter prospective study

Vizient, Inc. today announced an agreement with Fresenius Kabi to add an additional seven medications to its Novaplus Enhanced Supply program, part of Vizient’s private label pharmacy solution

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2020.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, has been invited to participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference,

MannKind Corporation announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.

Supporting a large collaboration of research organizations, the U.S. Department of Energy’s Argonne National Laboratory is exploring the use of artificial intelligence and high-performance computing resources to study, in great detail, the complex dynamics of the spike protein, one of the key proteins that allows the SARS-CoV-2 virus to infiltrate the human immune system.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share.

Amarin Corporation plc (NASDAQ:AMRN) today shared positive, statistically significant top-line results from Protocol Number EDPC003R01, a Phase 3 clinical trial of VASCEPA® (icosapent ethyl) conducted in China by Amarin partner, Edding.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, reported operational and financial results for the first quarter ended September 30, 2020.

Sotera Health Company today announced the pricing of its initial public offering (“IPO”) of 46,600,000 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds of the offering are expected to be approximately $1.1 billion, before deducting underwriting discounts and commissions and offering expenses